How to Reconstitute NAD+: A Laboratory Research Guide

Reconstitution of NAD+ refers to the preparation of a working solution from lyophilised β-nicotinamide adenine dinucleotide, the oxidised dinucleotide form of the compound. Synonyms encountered in the literature include nicotinamide adenine dinucleotide, NAD, and diphosphopyridine nucleotide (DPN); it is classified as a pyridine dinucleotide and a redox coenzyme rather than as a drug or a vitamin. The evidence block supplied for this page does not give a sequence, molecular formula, or molecular weight for NAD+, so no such values are stated here. Reconstitution is a laboratory bench procedure: the lyophilised solid is brought into solution in an appropriate solvent, and the resulting stock is handled according to the requirements of the assay in which it will be used.

The work described in the evidence centres on NAD+ as the substrate and product of oxidoreductase chemistry and on its role as a precursor pool for nicotinamide adenine dinucleotide-dependent enzymes; the clinical studies cited below examine oral NAD+ itself, and the related precursors nicotinamide, nicotinamide riboside, and nicotinamide mononucleotide, in human populations.

Research Studies

NAD+ and whole-blood NAD+ levels in healthy adults

A clinical trial has been designed to assess the absorption, safety, and efficacy of an oral NAD+ supplement in healthy adults [1]. The primary question the trial aims to answer is the change in NAD+ levels in whole blood from baseline to day 56, comparing the NAD+ supplement against placebo [1]. Participants are asked to complete questionnaires, provide blood samples, consume either the NAD+ supplement or a placebo for 55 days, and undergo evaluation of endothelial function [1]. This is a registered trial protocol; the evidence block does not report results.

Nicotinamide and retinal nerve cell layer thickness in primary open-angle glaucoma

The NADIR trial is investigating whether high-dose nicotinamide, a form of vitamin B3, can protect retinal nerve cells in adults with primary open-angle glaucoma (POAG) who are already receiving standard glaucoma eye drops or laser treatment [2]. The main question is whether adding nicotinamide to standard glaucoma therapy slows the rate of thinning of the inner retinal nerve cell layer, measured by a non-invasive eye scan, compared with standard therapy alone over 12 months [2]. Participants are randomly assigned to two groups; the treatment group takes nicotinamide tablets by mouth, starting at 1.5 grams per day [2]. The evidence block does not report outcomes.

Nicotinamide riboside and six-minute walk distance in peripheral artery disease

The NICE-PAD II trial is testing the hypothesis that participants with peripheral artery disease (PAD) aged 50 and older randomised to nicotinamide riboside (NR) will show greater improvement or less decline in six-minute walk distance at six-month follow-up compared with those randomised to placebo [3]. The study randomises 250 participants with PAD aged 50 and older to NR or placebo for six months [3]. The primary outcome is change in six-minute walk distance at six-month follow-up; secondary outcomes include Walking Impairment Questionnaire (WIQ) distance score, PROMIS Mobility score, and calf muscle perfusion measured by magnetic resonance arterial spin labelling [3].

Nicotinamide and post-COVID syndrome in patients with documented tryptophan deficiency

An observational study is examining CICR-NAM, a nicotinamide formulation developed as a food for special medicinal purposes, in patients with post-COVID syndrome [4]. The rationale notes that changes in tryptophan metabolism, energy metabolism, and the gut microbiome may occur in post-COVID syndrome, and that in an earlier nutritional study patients with COVID-19 recovered physical performance more quickly when taking nicotinamide, with responders developing post-COVID syndrome less frequently [4]. The CICR-NAM tablets were developed at the University Hospital Schleswig-Holstein in Kiel to release the active substance selectively in the lower intestine and have been reported as well tolerated in several studies [4]. Patients with post-COVID syndrome and documented tryptophan deficiency may therefore take the preparation [4].

MIB-626 (β-nicotinamide mononucleotide) in adults with Down syndrome

A study is determining the safety and tolerability of different increasing doses of MIB-626, a microcrystalline form of β-nicotinamide mononucleotide (NMN), given daily for 28 consecutive days to adults with Down syndrome [6]. The study also explores how the drug moves through the body over time (pharmacokinetics) and how it affects the body in different ways (pharmacodynamics) [6]. Participants are monitored for adverse events, with measurements including laboratory tests of blood counts, chemistries and coagulation profile, and electrocardiogram [6]. The trial is to enrol 24 adults with Down syndrome [6].

Topical niacinamide riboside and facial skin ageing

A trial is evaluating topical niacinamide riboside (topical NR, also known as nicotinamide riboside), described as an endogenous compound and a precursor to NAD+, on the signs of facial skin ageing [7]. The rationale cites research published by Maussudi et al. 2012 demonstrating that skin NAD+ levels were negatively correlated with age in both males and females, and that aged skin was also correlated with an increase in DNA damage [7]. It is proposed that supporting skin NAD+ with precursors such as NR may be a strategy to address DNA damage associated with undesirable signs of skin ageing, thereby supporting skin cell resilience [7]. The evidence block states that use of NR as a dietary supplement has produced effective, efficient, and reproducible results, without giving the underlying values [7].

Nicotinamide riboside and cerebral blood vessel health, memory and physical function in Parkinson's disease

A clinical trial is investigating whether nicotinamide riboside (NR), a form of vitamin B3, can improve blood vessel health in the brain, memory, and physical function in eligible participants [8]. NR is described as investigational for this study because it is not yet established for this specific use [8]. The main questions are whether NR can improve non-invasive measures of blood vessel health in the brain, and whether it can improve memory testing results and physical function [8]. Researchers are comparing participants who receive NR with participants who receive a placebo [8].

Comparison of NAD+ and precursor interventions across the cited trials

The table below sets out the compound, population, and primary or main outcome for each interventional study in the evidence block. It is a summary of registered protocols and does not report results.

Supporting observations from adjacent literature

One reference-only source in the evidence block concerns Guizhi Wuling Decoction, a combined prescription consisting of the classical formulas Wuling San and Guizhi Fuling Wan without modification, which has been clinically applied for cardiovascular diseases, with prior studies reporting cardioprotective and anti-fibrotic effects [9]. That paper reports an investigation of myocardial fibrosis and mitochondrial homeostasis using network pharmacology, molecular docking, and multi-omics integration [9]. It is included here as context for the broader mitochondrial and redox literature in which NAD+ chemistry sits; it does not report findings on NAD+ reconstitution or on any NAD+ precursor.

If you are reading this for personal health reasons

The material described on this page is sold for laboratory research use only, and nothing here is intended for human consumption. We do not provide dosing, administration, or medical guidance of any kind. Anyone considering a compound for their own health should speak to a licensed clinician.

Sources

• [1] A Clinical Trial to Assess the Absorption, Safety, and Efficacy of an Oral Nicotinamide Adenine Dinucleotide (NAD+) Supplement in Healthy Adults — https://clinicaltrials.gov/study/NCT07692633
• [2] Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial) — https://clinicaltrials.gov/study/NCT07808333
• [3] The NICE-PAD II Trial — https://clinicaltrials.gov/study/NCT07782671
• [4] Observational Study With CICR-NAM as a Food for Special Medicinal Purposes in Post-COVID Syndrome (PCS) — https://clinicaltrials.gov/study/NCT07798570
• [6] NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome — https://clinicaltrials.gov/study/NCT07278492
• [7] Efficacy of Topical Niacinamide Riboside on the Signs of Facial Skin Aging — https://clinicaltrials.gov/study/NCT07774000
• [8] NAD Supplementation in Parkinson's Disease — https://clinicaltrials.gov/study/NCT07703137
• [9] Guizhi Wuling Decoction alleviates myocardial fibrosis by restoring mitochondrial homeostasis: Evidence from network pharmacology, molecular docking, and multi-omics integration. — https://pubmed.ncbi.nlm.nih.gov/42462419/